TY - JOUR
T1 - Anti-ganglioside antibodies in a large cohort of European patients with systemic lupus erythematosus
T2 - Clinical, serological, and HLA class II gene associations
AU - Galeazzi, Mauro
AU - Annunziata, Pasquale
AU - Sebastlani, Gian Domenico
AU - Bellisai, Francesca
AU - Campanella, Valeria
AU - Ferrara, Gian Battista
AU - Font, Josep
AU - Houssiau, Frederic
AU - Passiu, Giuseppe
AU - De Ramon Garrido, Enrique
AU - Fernandez-Nebro, Antonio
AU - Bracci, Luisa
AU - Scorza, Raffaella
AU - Puddu, Pietro
AU - Jedryka-Goral, Anna
AU - Smolen, Josef
AU - Tincani, Angela
AU - Carcassi, Carlo
AU - Morozzi, Gabriella
AU - Marcolongo, Roberto
PY - 2000
Y1 - 2000
N2 - Objective. To assay anti-ganglioside antibodies (aGM1) in sera of a large cohort of European patients with systemic lupus erythematosus (SLE) to define the prevalence of these autoantibodies in SLE; to evaluate the association of aGM1 with clinical manifestations and other autoantibodies found in SLE; and to search for aGM1 association with HLA class II alleles. Methods. Four hundred forty-eight patients with SLE were consecutively enrolled in 8 centers from 6 European countries. All sera were tested for antinuclear antibodies by immunofluorescence on HEp-2 cells as substrate, anti-dsDNA, aGM1 aCL, aβ2-glycoprotein I (aβ2-GPI) antibodies by ELISA, and antineutrophil cytoplasmic antibodies (ANCA) by immunofluorescence and by ELISA. Genomic typing for HLA class II loci was performed by polymerase chain reaction-sequence specific oligonucleotide probe method. Clinical assessment was done at the time of enrolment. Results. We found 41.9% of patients with clinical signs of neuropsychiatric involvement; 15.5% of patients were positive for aGM:1, 8% of the IgG isotype and 8.6% of the IgM isotype; aGM1- IgG were associated with neuropsychiatric manifestations (NPM) (RR = 3.7), with migraine (RR = 2.4), with OBS (RR = 7.3), and with peripheral neuropathy (RR = 8.5). aGM1-IgM were associated with NPM (RR = 4) and with depression (RR = 3.4). Furthermore, the genetic study showed that aGM1-IgG were associated with HLA-DQB1*0404 (RR = 7.2) while aGM1-IgM were associated with HLA-DQB1*0605 (RR = 33.3). No associations were found between aGM1 and anti-dsDNA, aCL, aβ2GPI, or ANCA. Conclusion. Our results show aGM1 can be found in patients with SLE. aGm1 may play a pathogenetic role for some NPM in this condition.
AB - Objective. To assay anti-ganglioside antibodies (aGM1) in sera of a large cohort of European patients with systemic lupus erythematosus (SLE) to define the prevalence of these autoantibodies in SLE; to evaluate the association of aGM1 with clinical manifestations and other autoantibodies found in SLE; and to search for aGM1 association with HLA class II alleles. Methods. Four hundred forty-eight patients with SLE were consecutively enrolled in 8 centers from 6 European countries. All sera were tested for antinuclear antibodies by immunofluorescence on HEp-2 cells as substrate, anti-dsDNA, aGM1 aCL, aβ2-glycoprotein I (aβ2-GPI) antibodies by ELISA, and antineutrophil cytoplasmic antibodies (ANCA) by immunofluorescence and by ELISA. Genomic typing for HLA class II loci was performed by polymerase chain reaction-sequence specific oligonucleotide probe method. Clinical assessment was done at the time of enrolment. Results. We found 41.9% of patients with clinical signs of neuropsychiatric involvement; 15.5% of patients were positive for aGM:1, 8% of the IgG isotype and 8.6% of the IgM isotype; aGM1- IgG were associated with neuropsychiatric manifestations (NPM) (RR = 3.7), with migraine (RR = 2.4), with OBS (RR = 7.3), and with peripheral neuropathy (RR = 8.5). aGM1-IgM were associated with NPM (RR = 4) and with depression (RR = 3.4). Furthermore, the genetic study showed that aGM1-IgG were associated with HLA-DQB1*0404 (RR = 7.2) while aGM1-IgM were associated with HLA-DQB1*0605 (RR = 33.3). No associations were found between aGM1 and anti-dsDNA, aCL, aβ2GPI, or ANCA. Conclusion. Our results show aGM1 can be found in patients with SLE. aGm1 may play a pathogenetic role for some NPM in this condition.
KW - Anti-GM
KW - HLA
KW - Neuropsychiatric manifestations
KW - Systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=0033955159&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033955159&partnerID=8YFLogxK
M3 - Article
C2 - 10648029
AN - SCOPUS:0033955159
VL - 27
SP - 135
EP - 141
JO - Journal of Rheumatology
JF - Journal of Rheumatology
SN - 0315-162X
IS - 1
ER -